UPDATE: 9 Meters Biopharma (NMTR) Prices 46.154M Share Common Offering at $0.65/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
After-Hours Stock Movers 12/10: (TPGY) (GIK) (RMG) Higher; (AMPY) (NBRV) (QCOM) Lower (more...)
December 10, 2020 6:06 PM ESTToday's After-Hours Stock Movers:
TPG Pace Beneficial Finance Corp. (NYSE: TPGY) 75% HIGHER; entered into a definitive agreement with ENGIE New Business S.A.S., a wholly owned subsidiary of ENGIE S.A. (Engie), a multi-national utility with headquarters in France, to acquire its subsidiary EV Charged B.V. for a combination of cash and equity. EVBox is a leading global provider of smart charging solutions for electric vehicles with Europes largest installed base of charging solutions and the most advanced cloud-based software offering.
Amplify Energy Corp. (NYSE:... More
9 Meters Biopharma (NMTR) Announces Proposed Public Offering of Common Stock
December 10, 2020 5:07 PM EST9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option... More
9 Meters Biopharma (NMTR) Receives Orphan Drug Designation for NM-003, Proprietary Long-Acting GLP-2, for Prevention of aGvHD
December 9, 2020 7:38 AM EST9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to NM-003, a proprietary long-acting GLP-2 receptor agonist, for prevention of acute graft versus host... More
